A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Public ClinicalTrials.gov record NCT05351554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Study identification
- NCT ID
- NCT05351554
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kinevant Sciences GmbH
- Industry
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Interventions
- Namilumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2022
- Primary completion
- Nov 14, 2022
- Completion
- Dec 12, 2022
- Last update posted
- Apr 16, 2025
2022
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kinevant Study Site | Palo Alto | California | 94304 | — |
| Kinevant Study Site | Denver | Colorado | 80206 | — |
| Kinevant Study Site | New Haven | Connecticut | 06519 | — |
| Kinevant Study Site | Gainesville | Florida | 32610 | — |
| Kinevant Study Site | Iowa City | Iowa | 52242 | — |
| Kinevant Study Site | Baltimore | Maryland | 21234 | — |
| Kinevant Study Site | Boston | Massachusetts | 02115 | — |
| Kinevant Study Site | Ann Arbor | Michigan | 48109 | — |
| Kinevant Study Site | New York | New York | 10029 | — |
| Kinevant Study Site | Cleveland | Ohio | 44195 | — |
| Kinevant Study Site | Portland | Oregon | 97239 | — |
| Kinevant Study Site | Charleston | South Carolina | 29425 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05351554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05351554 live on ClinicalTrials.gov.